<code id='A91BF40D51'></code><style id='A91BF40D51'></style>
    • <acronym id='A91BF40D51'></acronym>
      <center id='A91BF40D51'><center id='A91BF40D51'><tfoot id='A91BF40D51'></tfoot></center><abbr id='A91BF40D51'><dir id='A91BF40D51'><tfoot id='A91BF40D51'></tfoot><noframes id='A91BF40D51'>

    • <optgroup id='A91BF40D51'><strike id='A91BF40D51'><sup id='A91BF40D51'></sup></strike><code id='A91BF40D51'></code></optgroup>
        1. <b id='A91BF40D51'><label id='A91BF40D51'><select id='A91BF40D51'><dt id='A91BF40D51'><span id='A91BF40D51'></span></dt></select></label></b><u id='A91BF40D51'></u>
          <i id='A91BF40D51'><strike id='A91BF40D51'><tt id='A91BF40D51'><pre id='A91BF40D51'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:6
          Merck's logo on an office building against the blue sky — coverage from STAT
          Adobe

          LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline. 

          Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.  

          advertisement

          EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine
          Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

          FILE-CaliforniaGov.GavinNewsomspeaksatanewsconferenceinSacramento,Calif.,onMarch16,2023.Newsomhadthr

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          How artificial intelligence is being used to detect, treat cancer

          3:26Alaboratorytechnicianconductsartificialintelligence(AI)-basedcervicalcancerscreeningatatestfacil